Four life stages for women's heart risk, one agreed definition for failing livers, and what a potassium pill does to blood pressure (2026)

Five documents published between October 26 and November 1, 2026 touch the three conditions this brief follows. Four medical societies put women's heart risk onto a four-stage map. Five liver societies agreed on a single definition of acute-on-chronic liver failure. A Lancet study tested 30 liver tests against biopsy. A meta-analysis measured what potassium pills do to blood pressure. And a national database compared GLP-1 drugs in people on dialysis.

These summaries are background for your next appointment. Your clinician knows your history, your labs, and your prescriptions, and treatment decisions belong in that conversation.

Quick view

Update	What changed	Who may care	Action window	Appointment question
Women's heart risk, in four life stages	On October 26 the American Heart Association, the American Academy of Pediatrics, ACOG, and the Society for Maternal-Fetal Medicine published a joint framework that splits a woman's life into four hormonal stages and treats menstrual patterns, pregnancy complications, and the menopause transition as heart-risk signals. 1	Women and girls of any age; especially anyone who had high blood pressure, preeclampsia, or gestational diabetes in pregnancy	Before your next primary care, OB-GYN, or cardiology visit	"I had a complicated pregnancy — does that change my heart risk now, and what should we check?"
One definition of acute-on-chronic liver failure	On October 30, five liver societies published one agreed framework, replacing regional definitions that used different thresholds. Liver failure now means an INR of at least 1.5 plus a bilirubin of at least 5 mg/dL, and severity is graded by how many other organs fail. 2 3	People with cirrhosis or advanced fibrosis, and their caregivers	This week — write down your baseline liver numbers	"If I get sick enough to be hospitalized, will my care team be using this new definition, and where would I be evaluated for transplant?"
Which liver test really finds scarring	The LITMUS study in The Lancet tested 12 single markers and 18 panels against biopsy in 1,590 adults. The authors set 0.80 as the accuracy a test must exceed to replace biopsy; only one panel cleared it for at-risk MASH, and several cleared it for cirrhosis. 4	Adults with fatty liver disease who have been told to "watch and wait"	Before your next visit, ask for the number	"Has a FIB-4 been calculated from my last blood work, and if it was high, what is the next test?"
Potassium pills and blood pressure	A review of 19 randomized trials in 803 adults with untreated high blood pressure found oral potassium lowered clinic blood pressure by 5.3/4.5 mm Hg, and 24-hour readings by less (2.8/3.2). Side effects were more common with potassium. 5	Adults with high blood pressure, especially anyone with kidney disease or a potassium-raising medicine	Before you buy any supplement	"Is my potassium level safe, and do any of my medicines make a supplement risky for me?"
Choosing a GLP-1 drug on dialysis	A target trial emulation in US dialysis data compared semaglutide with dulaglutide or liraglutide in about 3,200 patients. Semaglutide was linked to lower death and hospitalization rates, but the comparison against liraglutide alone was not conclusive. 6	Adults with type 2 diabetes on maintenance dialysis	At your next nephrology visit	"I'm on dialysis and on a GLP-1 drug — which one am I on, and is it the right choice for me?"

1. Women's heart risk now has four stages, and a pregnancy history counts

On October 26, four medical societies published three papers together in Circulation. 1 They came from the American Heart Association, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine. 1 It is the first time these specialties have issued a shared framework. 1 The presidential advisory that anchors it is separate from the clinical guidance. 7

The scale is why it matters. Cardiovascular disease is the leading cause of death in US women, at more than 400,000 deaths a year. 1 Only about 41 percent of women name it as their greatest health threat. 1

The framework divides a woman's life into four stages, each defined by a hormonal transition rather than a birthday. 1 Stage 1 runs from about age 8 to 15. Stage 2 covers the cycling years, roughly 15 to 44. Stage 3 is perimenopause, about 45 to 51. Stage 4 is postmenopause, from 51 on. 1 Pregnancy sits across all four, because it can unmask risk that was already there. 1

Three changes in practice matter most to a patient.

First, the menstrual cycle is treated as a vital sign. 8 Heavy or irregular bleeding can be an early clue to polyendocrine metabolic ovarian syndrome, the condition most people still call PCOS. 8 It can also point to iron deficiency, including iron deficiency without anemia. 8 Both conditions shape heart risk over decades. 1

Second, pregnancy history is heart history. High blood pressure in pregnancy, preeclampsia, gestational diabetes, preterm birth, a small-for-gestational-age baby, and stillbirth now count as female-specific risk enhancers. 1 The 2026 cholesterol guideline from the AHA and the American College of Cardiology already includes pregnancy factors when it estimates a woman's risk. 1

Third, perimenopause is a checkpoint. Screening for the menopause transition should start by age 40. 8 Its onset should trigger a full cardiovascular risk assessment, because cholesterol and metabolic measures shift during that window. 8 The years after menopause can make up 40 percent of a woman's lifetime, and most heart attacks, strokes, and heart failure events happen there. 1

There is also a warning about bleeding on heart medicine. During the cycling and perimenopausal years, an anticoagulant or dual antiplatelet therapy can cause or worsen heavy uterine bleeding. 8 Naming that in advance, and treating it, keeps people from quietly stopping the drug that protects them. 8

One gap the societies call out is close to home. Only about 60 percent of US women who had a blood-pressure complication in pregnancy get follow-up care for their blood pressure within six months of delivery. 1

Two limits belong here. This is a scientific statement, not a treatment guideline; AHA statements pull together evidence and shape later guidelines, but they do not issue drug recommendations. 1 And the life-stage framework is a way of organizing care, not a validated score that predicts your personal risk. 9

Ask at your next visit: "I had high blood pressure in pregnancy — does that change my heart risk now, and what should we measure besides my blood pressure today?"

2. One definition for the sickest liver patients, agreed by five societies

On October 30, five liver societies published a joint consensus on acute-on-chronic liver failure. 2 The signatories are AASLD, EASL, APASL, ALEH, and SOLDA, covering the United States, Europe, Asia, Latin America, and Africa. 2 It appeared in Hepatology and in three other journals at the same time. 10

Acute-on-chronic liver failure, usually shortened to ACLF, is what happens when someone who already has advanced liver disease suddenly fails, and other organs start failing too. 3 It carries a high risk of death within weeks, not years. 3

Until now, regional definitions disagreed on thresholds and outcomes, which made studies hard to compare. 3 The panel adopted only statements that at least 70 percent of its members endorsed. 3 For a patient, the practical effect is that the term will now mean the same thing in a community hospital and in a trial. 3

The new core is short. The underlying disease must be advanced, meaning fibrosis of stage 3 or worse. 3 The consensus sets liver failure at an INR of at least 1.5 together with a bilirubin of at least 5 mg/dL. 3 Liver failure is required; it is the center of the syndrome. 3

Severity is then graded by the extra organs involved. 3 Grade 1 is liver failure plus one organ dysfunction. Grade 2 is liver failure plus any one organ failure. Grade 3 is liver failure plus two or more organ failures. 3

The definition also settles what counts as an organ failure. Grade 3 or 4 hepatic encephalopathy counts. So does stage 2 or 3 acute kidney injury by KDIGO criteria, needing a ventilator, or needing vasopressors. 3

Triggers are listed too. Bacterial infection is the most frequent, followed by ongoing alcohol use, hepatitis B reactivation, drug-induced liver injury, gastrointestinal bleeding, and major surgery. 3 In a substantial share of cases, no trigger is ever found. 3

Two of the panel's decisions change care directly. Steroids should not be prescribed in grade 3 ACLF, where the chance of responding is very low; when two organs are failing, the chance is around 40 percent and decisions are made case by case. 3 And a minimum period of abstinence should not be required before someone with alcohol-related hepatitis is listed for transplant. 3

The transplant numbers explain why timing matters. In registry studies the panel reviewed, 90-day waitlist mortality was 21.6 percent overall, and 39 percent in grade 3b. 3 Carefully selected grade 3 patients who received a transplant reached one-year survival of about 75 to 84 percent. 3

One caution is written for patients, not researchers. During a suspected ACLF episode, elastography should not be used on its own to prove cirrhosis, because acute injury can inflate stiffness readings. 3

The limits are worth naming. A shared definition does not create a new treatment; it makes trials and comparisons possible. 3 The survival figures come from the cohort and registry studies the panel reviewed, not from a new trial. 3

What a person with cirrhosis can do this week is small and useful. Write down your baseline INR, bilirubin, and creatinine, and the hospital that manages your liver. 3 Sudden confusion, yellowing eyes, or a rapidly swelling abdomen is a call for urgent care, not a next-month appointment. 3

Ask at your next visit: "If I were hospitalized with a sudden decompensation, would my team be grading it with this new definition — and should we talk about transplant evaluation before that happens?"

3. Which liver test actually finds the dangerous fatty liver

The LITMUS study, published in The Lancet issue of October 31, put 30 liver tests up against biopsy. 4 It enrolled 1,590 adults with biopsy-confirmed fatty liver disease across 13 countries in Europe and the United States. 4

The tests ran from single blood markers to 18-marker panels. 4 Accuracy was scored with the area under the curve, a 0-to-1 measure where 0.5 means a test does no better than chance. 4

The authors set 0.80 as the minimum a test must beat to be considered a possible replacement for biopsy. 4

For the condition that matters most — at-risk MASH, meaning active inflammation plus at least moderate scarring — only one panel cleared that bar. 4 SomaSignal reached 0.83. No other test cleared it for MASH alone. 4

Advanced fibrosis was easier to find. 4 SomaSignal scored 0.92, FibroMeter-VCTE 0.87, Agile 3+ and TSP2 both 0.84, and NIS4 0.82. 4

Cirrhosis was easiest of all. 4 FibroMeter-VCTE led at 0.94, with SomaSignal at 0.92, Agile 3+ at 0.88, Agile 4 at 0.87, ADAPT at 0.85, and ELF, LSM-VCTE, and TSP2 each at 0.84. 4

Single markers, used alone, performed inconsistently. 4

The most usable finding is about sequencing, not brands. Two-step strategies that used GGT, a routine liver enzyme, as the first test met the bar for both advanced fibrosis and at-risk MASH. 4

VCTE in those names is the vibration-based scan most people know as FibroScan; ELF is a blood panel; the rest combine results into a score. 4

What most people already get is step one. A FIB-4 score is calculated from your age, AST, ALT, and platelet count, all of which usually sit in routine blood work. 11 It is cheap and fast, which is why primary care uses it to decide who needs a second test. 11

It is also imperfect. Alcohol raises AST, other conditions lower platelets, and scores are less reliable at older ages. 11 Used alone, a low score can still miss people who have advanced fibrosis. 11

The limits here are the population and the ruler. Everyone in LITMUS already had biopsy-confirmed fatty liver disease, so this measures accuracy in a selected group rather than in the general public. 4 And biopsy, the reference every test was scored against, is itself an imperfect sample of the whole liver. 11

You are unlikely to be offered the top-performing panel next week. What you can ask is where you are in the sequence, and what happens if your first number is high. 4

Ask at your next visit: "Has my FIB-4 been calculated from my last labs, and if it was high, which second test do we do next — and when?"

4. What a potassium pill does to blood pressure, and where it gets risky

On October 30, the Journal of the American Heart Association published a meta-analysis of 19 randomized trials of oral potassium. 5 The trials covered 803 adults with untreated high blood pressure, with a median duration of four weeks. 5

In the clinic, potassium lowered systolic pressure by 5.3 mm Hg and diastolic pressure by 4.5 mm Hg. 5 On 24-hour ambulatory monitoring, the drop was smaller: 2.8 and 3.2 mm Hg. 5

Side effects were more common in the potassium groups, 12.8 percent against 3.2 percent in the comparison groups, though few people stopped taking it. 5

The authors ask for restraint. Heterogeneity between trials was substantial, follow-up was short, and ambulatory and safety data were limited. 5

One design detail matters more than any of those numbers. Every trial enrolled people whose high blood pressure was untreated. 5 The review therefore says nothing about adding potassium to an existing drug regimen, which is the situation most readers are in. 5

The underlying idea is not new. Too much sodium and too little potassium can raise blood pressure, and potassium helps the body handle sodium. 12 Most of the potassium Americans eat comes from vegetables, fruit, seafood, and dairy. 12

The safety boundary is the part to take to a clinician. Your kidneys regulate potassium, so a supplement can be risky when they work less well. 13

Risk rises with chronic kidney disease, diabetes, and heart failure, and with medicines that shift potassium balance, including ACE inhibitors and ARBs. 13 A normal potassium level is 3.5 to 5.0 mmol/L, and hyperkalemia starts above 5.5. 13

Mild hyperkalemia often has no symptoms, which is what makes it dangerous. 13 Untreated, it can cause abnormal heart rhythms. 13

If you have been told to watch potassium, salt substitutes are a trap: they are usually potassium chloride. 13

So the useful reading of this paper is about food, not pills. Bananas, oranges, melons, potatoes, sweet potatoes, cooked spinach, and broccoli all carry potassium. 12

If a supplement is on your mind, ask for a potassium level first and ask whether any of your medicines make it unsafe. 13

Ask at your next visit: "When was my potassium last checked, and do any of my medicines mean I should avoid potassium supplements or salt substitutes?"

5. On dialysis, which GLP-1 drug may matter

A randomized trial in people on dialysis is hard to run, so researchers emulated one in national data. 6 The study, published in Diabetes Care on October 27, used US Renal Data System and Medicare records from 2011 to 2022. 6

It compared 1,312 people who started semaglutide with 2,601 who started dulaglutide or liraglutide. 6 After weighting, the effective sample was about 3,200 patients, with a mean age of 61 and a median follow-up of about 1.1 years. 6

Death on dialysis was lower with semaglutide. 6 The subdistribution hazard ratio was 0.82, and the one-year cumulative incidence was 11 percent against 13 percent. 6

All-cause hospitalization was also lower, with a ratio of 0.91 and a one-year incidence of 57 percent against 62 percent. 6

Weight loss at one year was greater with semaglutide, 4.8 percent against 3.4 percent. 6

The head-to-head results are more nuanced than the headline. 6 Against dulaglutide alone, the mortality and hospitalization differences held. Against liraglutide alone, they did not reach statistical significance. 6

That pattern suggests the finding may reflect differences among these drugs, or the different people who end up on them, rather than a clean advantage of one molecule. 6

The limits are the design. This is not a randomized trial; it is claims data weighted to look like one. 6 Claims show that a prescription was filled, not why it was chosen or whether the pills were taken. 6 Differences between the groups can survive even careful weighting. 6

Weight loss is what the study measured, not what it prescribed. 6 On dialysis, whether weight change helps depends on muscle mass and nutrition, which your team tracks separately.

Ask at your next visit: "I'm on dialysis and taking a GLP-1 drug — which one am I on, why that one, and is weight loss even a goal for me?"

Questions to bring to your next appointment

"I had high blood pressure in pregnancy — does that change my heart risk now, and what should we measure besides my blood pressure today?"
"If I were hospitalized with a sudden decompensation, would my team be grading it with the new ACLF definition, and should we discuss transplant evaluation beforehand?"
"Has my FIB-4 been calculated from my last labs, and if it was high, which second test do we do next — and when?"
"When was my potassium last checked, and do any of my medicines mean I should avoid potassium supplements or salt substitutes?"
"I'm on dialysis and taking a GLP-1 drug — which one am I on, why that one, and is weight loss even a goal for me?"

References

These summaries are background for your next appointment. Your clinician knows your history, your labs, and your prescriptions, and treatment decisions belong in that conversation.

Quick view

Update	What changed	Who may care	Action window	Appointment question
Women's heart risk, in four life stages	On October 26 the American Heart Association, the American Academy of Pediatrics, ACOG, and the Society for Maternal-Fetal Medicine published a joint framework that splits a woman's life into four hormonal stages and treats menstrual patterns, pregnancy complications, and the menopause transition as heart-risk signals. 1	Women and girls of any age; especially anyone who had high blood pressure, preeclampsia, or gestational diabetes in pregnancy	Before your next primary care, OB-GYN, or cardiology visit	"I had a complicated pregnancy — does that change my heart risk now, and what should we check?"
One definition of acute-on-chronic liver failure	On October 30, five liver societies published one agreed framework, replacing regional definitions that used different thresholds. Liver failure now means an INR of at least 1.5 plus a bilirubin of at least 5 mg/dL, and severity is graded by how many other organs fail. 2 3	People with cirrhosis or advanced fibrosis, and their caregivers	This week — write down your baseline liver numbers	"If I get sick enough to be hospitalized, will my care team be using this new definition, and where would I be evaluated for transplant?"
Which liver test really finds scarring	The LITMUS study in The Lancet tested 12 single markers and 18 panels against biopsy in 1,590 adults. The authors set 0.80 as the accuracy a test must exceed to replace biopsy; only one panel cleared it for at-risk MASH, and several cleared it for cirrhosis. 4	Adults with fatty liver disease who have been told to "watch and wait"	Before your next visit, ask for the number	"Has a FIB-4 been calculated from my last blood work, and if it was high, what is the next test?"
Potassium pills and blood pressure	A review of 19 randomized trials in 803 adults with untreated high blood pressure found oral potassium lowered clinic blood pressure by 5.3/4.5 mm Hg, and 24-hour readings by less (2.8/3.2). Side effects were more common with potassium. 5	Adults with high blood pressure, especially anyone with kidney disease or a potassium-raising medicine	Before you buy any supplement	"Is my potassium level safe, and do any of my medicines make a supplement risky for me?"
Choosing a GLP-1 drug on dialysis	A target trial emulation in US dialysis data compared semaglutide with dulaglutide or liraglutide in about 3,200 patients. Semaglutide was linked to lower death and hospitalization rates, but the comparison against liraglutide alone was not conclusive. 6	Adults with type 2 diabetes on maintenance dialysis	At your next nephrology visit	"I'm on dialysis and on a GLP-1 drug — which one am I on, and is it the right choice for me?"